e-3330 and Breast-Neoplasms

e-3330 has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for e-3330 and Breast-Neoplasms

Article	Year
The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Chemical biology & drug design, 2017, Volume: 90, Issue:4 The human apurinic/apyrimidinic endonuclease 1 (APE1) is an ubiquitous multifunctional DNA repair enzyme and a redox signalling protein. Our work addressed the inhibition of APE1 redox function using E3330, as single agent or in combination with docetaxel (DTX), in human breast cancer MDA-MB-231 cells. E3330 decreased the colony formation of DTX-treated cells. In addition, E3330 alone significantly reduced the collective cell migration as assessed by the wound-healing assay, whereas the combined treatment decreased chemoinvasion. These results suggest that the inhibition of APE1 redox function might have therapeutic potential by modulating cell migration and invasion in metastatic breast cancer. Topics: Antineoplastic Agents; Benzoquinones; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-(Apurinic or Apyrimidinic Site) Lyase; Docetaxel; Female; Humans; Neoplasm Invasiveness; Oxidation-Reduction; Propionates; Taxoids	2017

Article

Year

The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel.

Chemical biology & drug design, 2017, Volume: 90, Issue:4

The human apurinic/apyrimidinic endonuclease 1 (APE1) is an ubiquitous multifunctional DNA repair enzyme and a redox signalling protein. Our work addressed the inhibition of APE1 redox function using E3330, as single agent or in combination with docetaxel (DTX), in human breast cancer MDA-MB-231 cells. E3330 decreased the colony formation of DTX-treated cells. In addition, E3330 alone significantly reduced the collective cell migration as assessed by the wound-healing assay, whereas the combined treatment decreased chemoinvasion. These results suggest that the inhibition of APE1 redox function might have therapeutic potential by modulating cell migration and invasion in metastatic breast cancer.

Topics: Antineoplastic Agents; Benzoquinones; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-(Apurinic or Apyrimidinic Site) Lyase; Docetaxel; Female; Humans; Neoplasm Invasiveness; Oxidation-Reduction; Propionates; Taxoids

2017